HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research ...

Fintel reports that on March 27, 2025, HC Wainwright & Co. initiated coverage of RenovoRx (NasdaqCM:RNXT) with a Buy ...

Stock analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Corvus Pharmaceuticals in a ...

Fintel reports that on March 25, 2025, HC Wainwright & Co. downgraded their outlook for Opthea Limited - Depositary Receipt ( ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Mural Oncology (MURA) to $6 from $18 and keeps a Buy rating on the ...

CompanyOverview|NASDAQ:SOUN] The world of artificial intelligence is starting to spread to different areas of everyday life, ...

Lyell Immunopharma’s (LYEL) jumped over 8% on Friday as investors’ interest surged. Despite posting unimpressive Q4 results a ...

On Wednesday, H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and a $4.00 price target on Actinium Pharma (NYSE: ATNM) shares, falling within the broader analyst target range of $ ...

On Wednesday, H.C. Wainwright reiterated a Neutral rating on shares of Bolt Biotherapeutics , Inc. (NASDAQ:BOLT) following a review of the company’s latest clinical candidate, BDC-4182. The company, ...

On Monday, H.C. Wainwright reaffirmed a Buy rating on Benitec BioPharma (NASDAQ:BNTC) shares, maintaining a $28.00 price target. The stock has shown remarkable momentum, delivering a 225% return over ...